Dr Mesa talks to ecancer at ASCO 2025 about data he presented from the The Phase 3 SURPASS-ET trial.

This trial evaluated ropeginterferon alfa-2b versus anagrelide in patients with essential thrombocythaemia resistant or intolerant to hydroxyurea.

Ropeginterferon outperformed anagrelide, achieving the primary response endpoint in 42.9% of patients versus 6.0% (p=0.0001). It also led to greater improvements in blood counts, symptom control, spleen size, and a notable reduction in thrombotic and cardiovascular events.

Additionally, ropeginterferon reduced JAK2V617F allele burden and had fewer serious adverse events and treatment discontinuations.

These findings support ropeginterferon alfa-2b as a more effective and safer second-line treatment option for essential thrombocythemia.